C. Kent Osborne
C. Kent Osborne
Director/Professor, Duncan Cancer Center, Baylor College of Medicine
Verified email at bcm.edu - Homepage
Cited by
Cited by
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in …
MEH Hammond, DF Hayes, M Dowsett, DC Allred, KL Hagerty, S Badve, ...
Archives of pathology & laboratory medicine 134 (7), e48-e72, 2010
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ...
Annals of oncology 24 (9), 2206-2223, 2013
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer
JM Harvey, GM Clark, CK Osborne, DC Allred
Journal of clinical oncology 17 (5), 1474-1481, 1999
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy
X Li, MT Lewis, J Huang, C Gutierrez, CK Osborne, MF Wu, ...
Journal of the National Cancer Institute 100 (9), 672-679, 2008
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
AS Coates, EP Winer, A Goldhirsch, RD Gelber, M Gnant, ...
Annals of oncology 26 (8), 1533-1546, 2015
Tamoxifen in the treatment of breast cancer
CK Osborne
New England Journal of Medicine 339 (22), 1609-1618, 1998
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2–positive breast cancer
J Shou, S Massarweh, CK Osborne, AE Wakeling, S Ali, H Weiss, R Schiff
Journal of the National Cancer Institute 96 (12), 926-935, 2004
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a …
KS Albain, WE Barlow, S Shak, GN Hortobagyi, RB Livingston, IT Yeh, ...
The lancet oncology 11 (1), 55-65, 2010
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer
JC Chang, EC Wooten, A Tsimelzon, SG Hilsenbeck, MC Gutierrez, ...
The Lancet 362 (9381), 362-369, 2003
Diseases of the Breast
JR Harris, ME Lippman, CK Osborne, M Morrow
Lippincott Williams & Wilkins, 2012
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer
CK Osborne, V Bardou, TA Hopp, GC Chamness, SG Hilsenbeck, ...
Journal of the National Cancer Institute 95 (5), 353-361, 2003
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
CC Benz, GK Scott, JC Sarup, RM Johnson, D Tripathy, E Coronado, ...
Breast cancer research and treatment 24 (2), 85-95, 1992
Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer
DC Allred, GM Clark, R Elledge, SAW Fuqua, RW Brown, GC Chamness, ...
JNCI: Journal of the National Cancer Institute 85 (3), 200-206, 1993
The value of estrogen and progesterone receptors in the treatment of breast cancer
CK Osborne, MG Yochmowitz, WA Knight III, WL McGuire
Cancer 46 (S12), 2884-2888, 1980
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases
VJ Bardou, G Arpino, RM Elledge, CK Osborne, GM Clark
Journal of clinical oncology 21 (10), 1973-1979, 2003
Treatment of HER2-positive breast cancer: current status and future perspectives
CL Arteaga, MX Sliwkowski, CK Osborne, EA Perez, F Puglisi, L Gianni
Nature reviews Clinical oncology 9 (1), 16, 2012
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes
RM Lavinsky, K Jepsen, T Heinzel, J Torchia, TM Mullen, R Schiff, ...
Proceedings of the National Academy of Sciences 95 (6), 2920-2925, 1998
HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.
DC Allred, GM Clark, AK Tandon, R Molina, DC Tormey, CK Osborne, ...
Journal of Clinical Oncology 10 (4), 599-605, 1992
Steroid hormone receptors in breast cancer management
CK Osborne
Breast cancer research and treatment 51 (3), 227-238, 1998
Estrogen receptor–positive, progesterone receptor–negative breast cancer: association with growth factor receptor expression and tamoxifen resistance
G Arpino, H Weiss, AV Lee, R Schiff, S De Placido, CK Osborne, ...
Journal of the National Cancer Institute 97 (17), 1254-1261, 2005
The system can't perform the operation now. Try again later.
Articles 1–20